A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

2023-507874-42-00 Phase I and Phase II (Integrated) - Other Temporarily halted

Start 27 Aug 2024 · Status Temporarily halted · 1 EU/EEA countries · 3 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Temporarily halted
Participants planned 80
Countries 1
Sites 3

Multiple sclerosis

Key facts

Sponsor
Assistance Publique Hopitaux De Paris
Participant type
Healthy volunteers, Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
27 Aug 2024 → ongoing
Decision date (initial)
2024-03-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple sclerosis

VersionLevelCodeTermSystem organ class
20.0 SOC 10029205 Nervous system disorders 8
20.1 LLT 10039720 Sclerosis multiple 10029205
20.1 PT 10028245 Multiple sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Assistance Publique Hopitaux De Paris

Sponsor organisation
Assistance Publique Hopitaux De Paris
Address
Porte 23, 1 Avenue Claude Vellefaux 1 Avenue Claude Vellefaux
City
Paris Cedex 10
Postcode
75475
Country
France

Scientific contact point

Organisation
Assistance Publique Hopitaux De Paris
Contact name
Bruno STANKOFF

Public contact point

Organisation
Assistance Publique Hopitaux De Paris
Contact name
Sophie Courtial-Destembert

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 80 3
Rest of world 0

Investigational sites

France

3 sites · Ongoing, recruiting
Assistance Publique Hopitaux De Paris
Neurology, Num Voie 47 A 83, 47 Boulevard De L Hopital, Paris
Hospices Civils De Lyon
Neurology, 59 Boulevard Pinel, 69500, Bron
Hospices Civils De Lyon
Neurology, 59 Boulevard Pinel, 69500, Bron

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-08-27 2024-08-27

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-113403

Halt date
2024-10-29
Planned restart
2026-05-31
Member states concerned
France
Publication date
2026-01-05
Reason
Sponsor decision
Explanation
Due to difficulties encountered in sourcing experimental products, the sponsor decided to suspend enrolment in the study pending the establishment of a permanent supply chain with a partner for the supply of experimental products.
No patients initiated experimental treatment prior to the suspension of enrolment.
Follow-up measures
Contract negotiation with a potential industrial partner to supply experimental products
Benefit-risk balance changed
No
Treatment stopped
No

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-10 France Acceptable
2024-03-11
2024-03-18